期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

心力衰竭患者血浆尾加压素的变化 被引量：2

Plasma level of urotensin in heart failure patients
暂未订购
导出
摘要 目的 :检测心力衰竭 (心衰 )患者血浆尾加压素 (urotensinⅡ ,UTN)的变化 ,探讨其在心衰中的临床意义。方法 :心衰组30例 ,NYHA心功能为Ⅱ～Ⅲ级 ;对照组 19例 ,NYHA心功能分级Ⅰ级 ,采用放射免疫法测定血浆UTN。并作统计学分析。结果 :与对照组相比 ,UTN在治疗前心衰患者血浆中明显升高 (P <0 .0 1) ,并且不受年龄、性别、NYHA心功能分级和心脏疾病种类的影响 (P >0 .0 5 )。结论 :UTN是一个比较独立的危险因素 ,在心衰的诊断中有一定参考价值。 Objective:To investigate the change of plasma urotensin Ⅱ(UTN) levels in heart failure patients and its clinical significance.Methods:The UTN was measured in the plasma of 30 patients with heart failure(grade Ⅰ-Ⅲ by NYHA) and 19 controls(grade Ⅰ by NYHA),and the results were analyzed statistically.Results:The UTN was elevated in the plasma of heart failure patients(P<0.01) before treatment compared with that of the controls,and it was not related to the age,sex or heart function grade.Conclusions:Plasma UTN is a relatively independent risk factor,which is of use in the diagnosis of heart failure.
作者 周亚刚 张海婴 蒋克泉 伍旭升 张高峰 曹健敏
机构地区 上海市第五人民医院心内科 上海市第五人民医院检验科 上海市第五人民医院麻醉科
出处 《蚌埠医学院学报》 CAS 2004年第4期335-337,共3页 Journal of Bengbu Medical College
关键词 心力衰竭 充血性 尾加压素 heart failure,congestive urotensin Ⅱ
分类号 R541.61 [医药卫生—心血管疾病]
  • 相关文献

参考文献8

  • 1Ames RS,Sarau HM,Charabers JK,et al.Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14[J].Nature,1999,401(6 750):282～286.
  • 2Ng LL,Loke I,O′Brien RJ,et al.Plasma urotensin in human systolic heart failure[J].Circulation,2003,106(23):2 877～2 880.
  • 3Stirrat A,Gallagher M,Douglas SA,et al.Potent vasodilator responses to human urotensin-Ⅱ in human pulmonary and abdominal resistance arteries[J].Am J Physiol Heart Circ Physiol,2001,280(2):H925～H928.
  • 4Hillier C,Berry C,Polraic MC,et al.Effects of urotensin-Ⅱ in human arteries and veins of varying caliber[J].Circulation,2001,103(10):1 378～1 381.
  • 5Russell FD,Molenaar P,O′Brien DM,et al.Cardiostimulant effects of urotensin-Ⅱ in human heart in vitro[J].Br J Pharmacol,2001,132(1):5～9.
  • 6Zou Y,Nagai R,Yamazaki T,et al.Urotensin-Ⅱ induces hypertrophic responses in cultured cardiomyocytes from neonatal rats[J].FEBS Lett,2001,508(1):57～60.
  • 7李玲,袁文俊,潘秀颉,王伟忠,邱景伟,唐朝枢,唐朝枢.尾加压素对新生大鼠心肌细胞一氧化氮合成的影响[J].生理学报,2002,54(4):307-310. 被引量：7
  • 8Douglas SA,Worder SD,Cante KJ.Pharmacological characterization in the rat,mouse,dog and primate[J].J Cardiovasc Pharmacol,2000,36(7):163～166.

二级参考文献10

  • 1[1]Coulouarn Y, Lihrman I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H. Cloning of cDNA encoding the urotensinⅡprecursor in frog and human reveals intense expression of the urotensinⅡgene in motoneurons of the spinal cord. Proc Natl Acad Sci USA, 1998, 95:15803～15808.
  • 2[2]Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AN, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, Mcnulty DE, Ellis CE, Elshouragy NA, Shabon U, Trill JJ, Hay DWP, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-Ⅱis a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 1999, 401(6750):282～286.
  • 3[3]Russell FD, Molenaar P, O′Brien DM. Cardiostimulant effects of urotensin-Ⅱin human heart in vitro. Br J Pharmacol, 2001,132:5～9.
  • 4[4]Douglas SA,Ohlstein EH.Human urotensin-Ⅱ,the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med, 2000, 10:229～237.
  • 5[5]Kumar A, Brar R, Wang P, Dee L, Skorupa G, Khadour F, Schulz R, Parrillo JE. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol, 1999,276(1 Pt 2):R265～R276.
  • 6[6]Maclean MR, Alexander D, Seirrar A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, Pollard K. Contractile responses to human urotensin-Ⅱin rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol, 2000,130:201～204.
  • 7[7]Gray GA, Jones MR, Sharif I. Human urotensinⅡ increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci, 2001,69:175～180.
  • 8[8]Katano Y, Ishihata A, Aita T, Ogaki T, Horie T. Vasodilator effect of urotensinⅡ, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol, 2000,402(1-2):R5～R7.
  • 9[9]Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-Ⅱ in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol, 2000,131:1262～1274.
  • 10[10]Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science, 1992,257:387～389.

共引文献6

同被引文献29

引证文献2

二级引证文献3

蚌埠医学院学报
2004年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部